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ABSTRACT
Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease
of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for
onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clin-
ical presentation, severity of neurologic disability following relapses, and variability of therapeutic
response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports
the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease
activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers
for patients with seronegative NMO have yet to be defined and validated. Collaborative interna-
tional studies hold great promise for establishing and validating biomarkers that are useful in ther-
apeutic trials and clinical management. In this review, we discuss known and potential biomarkers
for NMO. Neurol Neuroimmunol Neuroinflamm 2015;2:e134; doi: 10.1212/NXI.0000000000000134
GLOSSARY
AQP4 5 aquaporin-4; BAFF 5 B-cell activating factor; BBB 5 blood-brain barrier; CBA 5 cell-based assay; GFAP 5 glial
fibrillary acidic protein; ICAM-1 5 intercellular adhesion molecule-1; IFN 5 interferon; IL 5 interleukin; MMP-9 5 matrix
metalloproteinase-9; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NF 5 neurofilament; NMO 5
neuromyelitis optica; NMOSD 5 NMO spectrum disorder; ON 5 optic neuritis; OSMS 5 opticospinal MS; TH 5 T helper cell;
VCAM-1 5 vascular cell adhesion molecule-1; VEGF-A 5 vascular endothelial growth factor-A.
Neuromyelitis optica (NMO) (and NMO spectrum disorder [NMOSD]) is an inflammatory
autoimmune disease of the CNS.1 It was first described in the 19th century by Gault and Devic,
among others.2 NMO usually presents with acute or repeated episodes of optic neuritis (ON)
and longitudinal transverse myelitis.3 It presents less commonly as a unique area postrema
syndrome accompanied by intractable vomiting and hiccups.4 NMO/NMOSD may be mon-
ophasic; however, the frequency of truly monophasic disease is difficult to estimate, as interval
attacks may last several years.5,6 The incidence of NMO is highest during the third to fourth
decade of life, with a considerably higher frequency among females (female-to-male ratio as high
as 9–10:1).7
Detection of complement-fixing antibodies directed against aquaporin-4 (AQP4; also known
as AQP4-IgG or NMO-IgG) in the majority of patients with the NMO clinical syndrome has
highlighted NMO/NMOSD as a distinct disease entity from multiple sclerosis (MS).8,9 Exten-
sive research has now established significant differences in the clinical, immunologic, histopath-
ologic, and imaging characteristics between NMO/NMOSD and MS.10–12
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Presence of AQP4-IgG has also facilitated
the diagnosis and early treatment of patients
with NMO/NMOSD. However, studies corre-
lating serum AQP4-IgG titers with disease
activity, severity, outcome, and response to
therapy have yielded inconsistent results.13–15
The search for additional biomarker candidates
in NMO has resulted in several interesting
leads, though they remain to be further vali-
dated.16,17 In this article, we will review the
current landscape of biomarker(s)/biomarker
candidates in NMO and NMOSD, consider
their clinical implications, and propose poten-
tial analytic platforms for future NMO bio-
marker discovery, validation, and application.
DESIGN OF LITERATURE REVIEW Along with man-
ual literature review by authors with expertise in the
field, published peer-reviewed articles were
interrogated to assess the current knowledge about
biomarkers in NMO/NMOSD. A search of the
PubMed database (National Center for Biotechnology
Information, US National Library of Medicine) was
performed using the query terms “biomarker,”
“NMO,” “opticospinal multiple sclerosis (OSMS),”
“blood,” “serum,” and “CSF.” NMO and NMOSD
met the criteria proposed by Wingerchuk et al.18 The
analysis included published literature up to 2014.
Although it was not possible to cite every published
report in this review, all of the meritorious efforts to
discover and validate potential biomarkers in NMO/
NMOSD are appreciated. Every effort was made to
highlight universally accepted themes. See the figure
for a summary of biomarker candidates in NMO and
MS and their current evidence levels.
I. AQP4-IGG AND OTHER SEROLOGIC MARKERS
AQP4-IgG/NMO-IgG. AQP4-IgG was the first
proposed biomarker of NMO/NMOSD and has
become a sine qua non of NMO diagnosis. Given
Figure Summary of relative biomarkers candidate levels in CSF and sera of NMO and MS patients
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its high specificity, NMO-IgG was added as a
supportive criterion in the revised 2006 NMO
diagnostic criteria.18 To date, AQP4 is the main
clinically approved biomarker for NMO. AQP4, the
most abundant water channel in the CNS, is found
predominantly on astrocyte foot processes forming the
glia limitans of the blood-brain barrier (BBB) and
around synapses at nodes of Ranvier.19 The AQP4
protein is highly expressed in the brainstem,
hypothalamus, diencephalon, spinal cord, and optic
nerves, correlating with the frequent distribution of
NMO lesions.20 AQP4 is also found in kidney,
stomach, placenta, and more isolated regions of the
CNS (such as granular layer of the cerebellum,
hippocampus, and globus pallidus), but most of
these tissues are not known to be involved in NMO/
NMOSD.21,22 Extensive experimental evidence
supports an important contribution of AQP4-IgG to
disease pathogenesis.23–26 It is evident that NMO-IgG
from the systemic circulation enters the CNS through
a disrupted BBB; however, it is also possible that anti-
APQ4 is generated intrathecally.24,25,27 The latter
scenario has implications for potential detection of
AQP4-IgG in CSF vs serum. AQP4-IgG (primarily
IgG1 subclass) binds avidly to AQP4, resulting in
complement fixation, generation of chemotactic
signals (e.g., C3a, C5a), immune cell infiltration, and
subsequent loss of AQP4 and glial fibrillary acidic
protein (GFAP) in astrocytes.28–31
Detection of AQP4-IgG has improved over the
past decade. First-generation tissue-based immuno-
fluorescence assays had relatively low sensitivity
(48%–54% for a single assay or 72% in a combina-
tion assay using recombinant human AQP4 ELISA
and transfected cell-based assays [CBAs]) and speci-
ficity of up to 100%.32–34 Newer techniques, such as
optimized immunohistochemistry assay, can detect
AQP4-IgG with 74.8% sensitivity and 100% speci-
ficity.35 Antibody directed against the M23 isoform of
AQP4 in orthogonal arrays has been reported to have
the highest sensitivity for the diagnosis of NMO/
NMOSD.36 Live CBAs, particularly those using the
M1-AQP4 isoform as antigen, have had the lowest
false-positive rates.37 The importance of assay meth-
odology for the differential diagnosis of NMO vs MS
has recently been underscored by the findings of
Pittock et al.,38 suggesting caution in interpretation
of results obtained using ELISA.
AQP4-IgG assessment can be helpful with disease
monitoring in certain cases. AQP4-IgG is found in
74% of recurrent NMO cases,39 and initial seropos-
itivity correlates with higher relapse rates than sero-
negative status.9 Of interest, AQP4-IgG can predate
clinical symptoms by up to 10 years.40 Patients with
NMO often benefit from plasmapheresis, presumably
due to reduction in circulating AQP4-IgG and/or
other circulating soluble factor(s).41,42 However, the
utility of monitoring AQP4-IgG titers during a dis-
tinct clinical relapse is less clear. AQP4-IgG titers also
may not predict extent of spinal disease.14,43 Immu-
nosuppressive therapies (such as azathioprine, cyclo-
phosphamide, or rituximab) can lower AQP4-IgG
titers during remission; however, disease quiescence
can occur with persistently high NMO-IgG titers.44
Currently, NMO-IgG titers do not appear to be a
reliable indicator of disease activity or prognosis.
Larger longitudinal studies will establish criteria for
and usefulness of serial NMO-IgG testing.
Despite the clinical utility of AQP4-IgG in NMO
diagnosis, several caveats preclude its use as a univer-
sal NMO biomarker. Approximately 20%–30% of
patients with the clinical syndrome of NMO lack
detectable AQP4-IgG, while in older studies up to
5%–10% of patients with MS were AQP4-IgG pos-
itive; however, seronegative cases have significantly
decreased with the use of newer CBAs.9,45 AQP4-
IgG seropositivity also varies widely based on geo-
graphic location and ethnicity. Among Caucasians,
56%–73% of patients with NMO/NMOSD are
AQP4-IgG positive,9,46,47 whereas 33.3% of Carib-
bean patients, 47% of Italian patients, 63%–90%
of Japanese patients, and 70%–76.9% of Chinese
patients are seropositive.48–51 The wide variability in
serostatus may reflect multiple factors, including eth-
nicity, sex, age, disease activity, immune therapies,
and variations in assay techniques.52 Collectively,
the complexities associated with use of AQP4-IgG
as a standard biomarker in NMO/NMOSD empha-
size the importance of optimization and standardiza-
tion of assays and clinical diagnostic criteria.
Anti-MOG and other autoantibodies in AQP4-IgG–
seronegative cases. Recently, additional autoantibodies
have gained attention as candidate biomarkers of
NMO/NMOSD, particularly in seronegative cases.
Antibodies against myelin oligodendrocyte glycoprotein
(MOG-IgG) have been observed in 20%–40% of pedi-
atric patients with acute disseminated encephalomyeli-
tis, ON, and relapsing demyelination disorders,
including NMO/NMOSD.53–55 MOG localizes to
the outer surface of oligodendrocytes and the myelin
sheath.56 Mader et al.57 first reported anti–MOG-IgG
in a proportion of AQP4-IgG–seronegative adult and
pediatric patients with NMO/NMOSD.Most recently,
Ramanathan et al.58 found a strong association between
anti-MOG antibodies and bilateral relapsing ON in
AQP4-IgG–seronegative patients (sensitivity 69%,
specificity 99% in their retrospective adult patient
cohort). In their study, MOG-IgG–seropositive
patients tended to be younger females with a
preceding infection and a relapsing course.
Monophasic nature in anti-MOG–seropositive cases
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has also been reported.59,60 Currently, the exclusive
expression of AQP4-IgG or MOG-IgG in individual
patients with NMO is suggested; however, improved
assay conditions in larger randomized cohorts are
needed to shed light on MOG-IgG’s utility as a
biomarker in AQP4-IgG–negative NMO/NMOSD
cases and the relationship between these 2 biomarkers.
Other reported autoantibodies in NMO/NMOSD
include NMDA-type glutamate receptor (e.g., CV2/
CRMP5) and glycine receptor antibodies.e1–e4 Anti-
bodies against other aquaporin proteins (e.g., AQP1)
also appear to be promising.e5 Autoantibody panels
(e.g., presence of anti–acetylcholine receptor, anti-
thyroid, and anti-nuclear antibodies) may be impor-
tant in understanding the connection between NMO/
NMOSD and coexisting autoimmune diseases such
as myasthenia gravis, autoimmune thyroid disorders,
and lupus.e6
II. B CELLS B cell dysregulation appears to be at the
core of NMO/NMOSD pathogenesis. For instance, B
cells expressing anti-AQP4 antibodies in the CSF and
elevated levels of circulating plasmablasts are found in
patients with acutely active NMO.17,23,e7 Specific B cell
subsets have been implicated as potential biomarker
candidates during relapses in patients with NMO.
For example, CD1381HLA-DR1 plasmablasts are
more abundant in the peripheral blood of patients
with NMO and are enriched in the fraction of CSF
lymphocytes during a relapse.e7 From a therapeutic
standpoint, efficacy of an anti-CD20 monoclonal
antibody (rituximab) may be related to the
magnitude of B cell depletion and the repopulation
of memory B cells.e8 Interleukin (IL)-6 signaling
plays an important role in antibody-producing
plasmablast survival and has an impact on the
germinal center maturation of memory B cells in
NMO.17 Alternatively, inhibition of IL-6 signaling
may inhibit T helper 17 (TH17) cell differentiation,
an effector T cell type implicated in NMO
pathogenesis.e9 Recent clinical studies also suggest
that administration of a monoclonal antibody
targeting the IL-6 receptor (tocilizumab) may have
clinical benefits in NMO.e10,e11 Indeed, the depletion
of proinflammatory IL-6–secreting B cells may
underpin the therapeutic benefit of rituximab, as
plasmablasts and plasma cells do not display CD20
and NMO-IgG titers are generally uninfluenced by
rituximab therapy.e12,e13 Future focused analyses of B
cell subsets (surface biomarkers, idiotype, and affinity
maturation) will be necessary to identify and validate a
prognostic or therapeutic B cell biomarker in NMO.
III. CYTOKINES, CHEMOKINES, AND OTHER
MOLECULARMARKERSOF INFLAMMATION Circula-
ting soluble mediates as well as B and T cell subsets, cells
of myeloid lineage, and deposition of immunoglobu-
lin (IgG and IgM) complement present in the target
organ suggest the participation of multiple cell types
in the pathogenesis of NMO.29,30 However, the tim-
ing and contribution of each player remain to be
determined as we learn more about the pathogenesis
of NMO. On the one hand, presence of autoanti-
bodies, high levels of serum IL-5 and CCL24
(eotaxin-2), CCL26 (eotaxin-3) in the CSF, B-cell
activating factor (BAFF) in serum and CSF, and
infiltration of granulocytes suggest involvement of a
TH2 cellular immune response in NMO/
NMOSD.e14,e15 In addition, there appears to be
enhanced expression of TH17-related (e.g., as IL-
17A, IL-6) and TH1-related (e.g., interferon [IFN]-
g) cytokines in some NMO/NMOSD cohorts.e16,e17
Increased levels of additional inflammatory
mediators, including IL-1 receptor antagonist, IL-6,
CCL8 (IL-8), IL-13, granulocyte colony-stimulating
factor (GCSF), High Mobility Group Box 1 Protein,
CXCL13 (BLC), CXCL10 (IP-10), and IL-13–
responsive chitinase, have also been detected in the
serum or CSF of patients with NMO.e18,e19 In
addition, cytokine and chemokine profile
differences between NMO/NMOSD and MS have
been examined and may prove useful as future
diagnostic biomarkers.e20–e22 Despite the differential
expression of these inflammatory markers in the
serum of patients with NMO, these markers are
also observed in other systemic and inflammatory
conditions; thus, the specificity and utility of these
biomarkers in NMO remain to be investigated
further.
IV. MARKERS OF BBB BREAKDOWN Circulating
AQP4-IgG may enter the CNS via the disrupted
BBB28,30 or may be generated intrathecally.e7
Regardless, factors indicative of BBB integrity may
serve as surrogate markers of NMO disease activity.
One candidate is matrix metalloproteinase-9 (MMP-9),
which participates in degradation of collagen IV
and is a major component of cerebral vascular
endothelial basement membrane.e23–e25 Higher serum
levels of MMP-9 were reported in patients with NMO
compared with patients with MS in a Japanese cohort,
and MMP-9 may increase BBB permeability in NMO
via an autocrine effect on CNS microvascular
endothelial cells.e26 A second NMO marker of BBB
breakdown, vascular endothelial growth factor-A
(VEGF-A), counterregulates claudin-5 and occludin
at vascular tight junctions. VEGF-A has been
implicated in promoting BBB breakdown in
demyelinating disorders.e27–e31 A Japanese study
found that patients with MS displayed higher serum
VEGF-A levels than healthy controls during an acute
relapse, with the highest levels in individuals with
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opticospinal lesions. Of interest, sera from relapsing
patients with NMO induced permeability in an
in vitro BBB model, which was reversed by
application of an anti–VEGF-A- blocking antibody,
suggesting the potential role of VEGF-A in NMO
pathology.e32 This effect was higher in sera from
AQP4-IgG–seronegative patients with NMOSD
than seropositive patients, implying factor(s) other
than AQP4-IgG regulate BBB perturbation in NMO.
Other BBB-regulating factors include adhesion
molecules, notably intercellular adhesion molecule-
1 (ICAM-1) and vascular cell adhesion molecule-
1 (VCAM-1), which also play important roles in
lymphocyte migration into the CNS.e33–e35 Higher
CSF levels of soluble ICAM-1 and soluble VCAM-
1 have been reported in patients with relapsing NMO
compared with patients with MS or healthy controls
and correlate with CSF albumin quotient.e36 Collec-
tively, markers of BBB breakdown present another
avenue of potential biomarkers in NMO/NMOSD,
and future studies are warranted to establish their
sensitivity/specificity.
V. TH LYMPHOCYTE RESPONSE IN NMO Another
body of emerging evidence points to critical roles for
T lymphocyte subsets in the pathogenesis of NMO/
NMOSD. There appears to be a direct relationship
between T activation, expansion, and enhanced expres-
sion of TH1, TH17 cytokines, and APQ4-specific T
cells.e37 Furthermore, presence of APQ4-specific T
cells has been observed.e38,e39 IFN-g–producing
T cells were overrepresented compared with IL-4–
expressing lymphocytes in the peripheral blood
mononuclear cells in patients with OSMS during
relapse.e40,e41 Elevated IL-17 (from TH17 cells) and
CXCL8 levels in CSF were also observed in patients
with OSMS and correlated with extent of spinal cord
lesions in NMO.e42 IL-17, IFN-g, and GCSF levels
were elevated in the CSF of patients with OSMS
regardless of their AQP4-IgG serostatus.e43 Recent
findings also suggest that CD41: CD81 T cell ratios
may be of interest in understanding NMO/NMOSD
pathogenesis and therapeutic efficacy, as shown by
reduction in ratio following rituximab therapy during
NMO relapse.e44 Moreover, regulatory T cell expansion
also correlated with NMO remission following anti-
CD20 therapy.e45 However, a comprehensive analysis
of the expression, function, and fate of T cell subsets
and their corresponding inflammatory mediators in
NMO remains to be conducted.
VI. CNS PROTEINS AS BIOMARKERS CNS pro-
teins are detected in sera and CSF of patients with
NMO/NMOSD, likely as part of compromised
BBB and tissue damage. Neurofilament (NF)
heavy-chain levels have been implicated in
inflammatory optic neuropathies in NMO/
NMOSD, with high serum NF levels correlating
with poor clinical outcome.e46 In addition, GFAP
and S100B are astrocytic markers detected in the
CSF in several inflammatory CNS disorders,
including NMO, and are both elevated in AQP4-
IgG–seropositive patients.e47–e49 CSF and serum
levels of S100B correlated with active NMO
disease, suggesting that S100B may be a potential
biomarker of acute relapse in seropositive NMO.
IL-6 and GFAP may also correlate with onset of
NMO attack.e50 Other studies have suggested that
CSF haptoglobin levels may be a biomarker
candidate for diagnosis or disease severity in NMO.e51
VII. GENETIC BIOMARKERS To date, as in most
autoimmune conditions, there is no direct relation-
ship between any individual gene or gene locus and
NMO/NMOSD, suggesting multifactorial etiology
with interplay from environmental triggers. Genetic
susceptibility loci include HLA-DPB1,e52 HLA-
DRB1*03:01,e53,e54 PD-1.3A allele of PTPN22,e55
and CD226 Gly307Ser.e56 CYP7A1 gene G/G
genotype compared with T/G genotype may have a
protective gene dose-dependent effect on the risk of
NMO.e57 It is interesting that the HLA-DRB1*1501
allele, which is associated with MS, does not appear to
be associated with NMO.e58 Also, no common single
nucleotide polymorphism in AQP4 appears to be
associated with NMO.e59 Hence, although all of the
above examples offer reasonable insights, additional
studies in larger cohorts are necessary to explore
potential genetic contributions to NMO/NMOSD.
VIII. COMPOSITE BIOMARKEREVALUATION Beyond
assessment of individual biomarkers, it may be useful
to explore composite biomarkers and/or biomarker
signatures in a complex disease such as NMO/
NMOSD. Pattern analysis applied to proteomic data
from NMO/NMOSD and MS has suggested com-
posite signatures that differentiate these diseases,
especially during relapse.e60 Similarly, mass spectrom-
etry and proteome network analyses have been used
to generate hypothetical composite biomarkers for
potential investigation in NMO/NMOSD,e61
MS,e62 and systemic lupus erythematosus.e63 As with
all biomarker discovery or validation efforts, optimal
study design is paramount, and any definitive inter-
pretations or conclusions will await prospective
masked investigations, preferably among ideally
matched and sufficiently large patient cohorts and
using optimally standardized methods.
IX. RELATIONSHIP TOCLINICALDISABILITY Beyond
insights into molecular or cellular immunopathology
of NMO/NMOSD, further biomarkers are needed to
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help predict disease activity and outcomes. Current
potential markers include BAFF, a proliferation-
inducing ligand, and osteopontin, which correlate
with disability in NMO but not MS.e15,e64 In
addition, CSF levels of CXCL13 (BLC) appear to
be elevated in direct proportion to relapse rates and
correlate with disability in patients with NMO.e22
While more investigation will be necessary to
ascertain their clinical relevance, the intersection of
biomarkers and disease status represents an important
and unmet patient need.
CONCLUSION Sensitive and specific biomarkers are
essential for diagnosis, prediction of relapses, progno-
sis of disease course, and therapeutic response in
NMO. If validated, biomarker candidates identified
in recent studies will pave the way to a better under-
standing of NMO pathogenesis. Moreover, they hold
promise for greater diagnostic accuracy and individu-
alized care. AQP4-IgG is the best biomarker of NMO
to date; however, standardization and optimization of
assays are needed. Future investigation into anti-
MOG and other non-AQP4 autoantibodies should
adjudicate whether these are clinically useful,
especially in the context of AQP4-IgG–seronegative
cases. Prospective research into T and B lymphocyte
immunobiology, cytokine and chemokine profiles,
antioxidants, markers of CNS and BBB damage, and
genomics/proteomics are expected to accelerate
biomarker discovery and validation. In this regard,
collaborative longitudinal international biomarker
studies with sufficient sample sizes to ensure
statistical power should enhance methodologic
standardization and promote consistent diagnostic
accuracy worldwide. In turn, these advances will
support the most informative clinical trials to
improve therapies and address unmet needs for
patients with NMO and NMOSD. Although
beyond the scope of the current review, future efforts
should also include delineation of the utility of imaging
and post mortem neuropathologic examination in
predicting clinical disability in NMO/NMOSD.
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